SQZ Biotechnologies Co (SQZ Biotechnologies Co) EBIT per Share : $-2.06 (TTM As of Sep. 2023)

View and export this data going back to 2020. Start your Free Trial

What is SQZ Biotechnologies Co EBIT per Share?

SQZ Biotechnologies Co's EBIT per Share for the three months ended in Sep. 2023 was $-0.55. Its EBIT per Share for the trailing twelve months (TTM) ended in Sep. 2023 was $-2.06.

During the past 3 years, the average EBIT per Share Growth Rate was -11.20% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.

The historical rank and industry rank for SQZ Biotechnologies Co's EBIT per Share or its related term are showing as below:

SQZB' s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -20.8 Med: -16 Max: -11.2
Current: -11.2

During the past 5 years, the highest 3-Year average EBIT per Share Growth Rate of SQZ Biotechnologies Co was -11.20% per year. The lowest was -20.80% per year. And the median was -16.00% per year.

SQZB's 3-Year EBIT Growth Rate is ranked worse than
66.74% of 1308 companies
in the Biotechnology industry
Industry Median: 3.4 vs SQZB: -11.20

SQZ Biotechnologies Co's EBIT for the three months ended in Sep. 2023 was $-16.12 Mil.

SQZ Biotechnologies Co EBIT per Share Historical Data

The historical data trend for SQZ Biotechnologies Co's EBIT per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

SQZ Biotechnologies Co EBIT per Share Chart

SQZ Biotechnologies Co Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

EBIT per Share

-1.33

-1.91

-9.45

-2.49

-2.63

SQZ Biotechnologies Co Quarterly Data
	Dec18	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23
EBIT per Share	Get a 7-Day Free Trial														-0.79	-0.31	-0.62	-0.58	-0.55

SQZ Biotechnologies Co EBIT per Share Calculation

EBIT per Share is the amount of Earnings Before Interest and Taxes (EBIT) per outstanding share of the company's stock.

Earnings Before Interest and Taxes (EBIT) is what the company earns before it expenses interest and taxes.

SQZ Biotechnologies Co's EBIT per Share for the fiscal year that ended in Dec. 2022 is calculated as

	EBIT per Share		(A: Dec. 2022 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-75.825	/	28.813
=	-2.63

SQZ Biotechnologies Co's EBIT per Share for the quarter that ended in Sep. 2023 is calculated as

	EBIT per Share		(Q: Sep. 2023 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-16.118	/	29.491
=	-0.55

EBIT per Share for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-2.06

SQZ Biotechnologies Co (OTCPK:SQZB) EBIT per Share Explanation

EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.

SQZ Biotechnologies Co EBIT per Share Related Terms

Thank you for viewing the detailed overview of SQZ Biotechnologies Co's EBIT per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

SQZ Biotechnologies Co (SQZ Biotechnologies Co) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » SQZ Biotechnologies Co (OTCPK:SQZB) » Definitions » EBIT per Share

Comparable Companies

Traded in Other Exchanges

N/A

Address

200 Arsenal Yards Boulevard, Suite 210, Watertown, MA, USA, 02472

Website

https://www.sqzbiotech.com

SQZ Biotechnologies Co is a clinical-stage biotechnology company developing transformative cell therapies for patients with cancer, infectious diseases, and other serious conditions. Using its proprietary technology, SQZ has the ability to deliver multiple materials into many patient cell types to engineer what it believes to be an unprecedented range of potential therapeutics for a range of diseases. The company has the potential to create well-tolerated cell therapies that can provide therapeutic benefit for patients and potentially improve the patient experience over existing cell therapy approaches, with accelerated production timelines under 24 hours and the elimination of preconditioning and lengthy hospital stays.

Executives

Richard Capasso	officer: See Remarks	C/O SQZ BIOTECHNOLOGIES COMPANY, 200 ARSENAL YARDS BOULEVARD, SUITE 210, WATERTOWN MA 02472
Marshelle Smith Warren	officer: Chief Medical Officer	C/O SQZ BIOTECHNOLOGIES COMPANY, 200 ARSENAL YARDS BOULEVARD, SUITE 210, WATERTOWN MA 02472
Klavs F. Jensen	director	C/O SQZ BIOTECHNOLOGIES COMPANY, 200 ARSENAL YARDS BOULEVARD, SUITE 210, WATERTOWN MA 02472
Amy W Schulman	director, 10 percent owner	PFIZER INC. ATTN: CORPORATE SECRETARY, 235 EAST 42ND STREET, NEW YORK NY 10017
Bernard Coulie	director	C/O PLIANT THERAPEUTICS, INC., 260 LITTLEFIELD AVENUE, SOUTH SAN FRANCISCO CA 94080
Vink Patrick V.j.j.	director	ETZELSTRASSE 20, 8707 UETIKON AM SEE V8 V8
Temasek Holdings (private) Ltd	10 percent owner	60B ORCHARD ROAD #06-18 TOWER 2, THE ATRIUM@ORCHARD, SINGAPORE U0 238891
Invus Public Equities, L.p.	10 percent owner	C/O THE INVUS GROUP, LLC, 750 LEXINGTON AVENUE, 30TH FLOOR, NEW YORK NY 10022
American International Group, Inc.	10 percent owner	1271 AVE OF THE AMERICAS, FL 37, NEW YORK NY 10020-1304
Polaris Entrepreneurs' Fund Vii, L.p.	10 percent owner	ONE MARINA PARK DRIVE, 10TH FLOOR, BOSTON MA 02210
S.a. Westend	10 percent owner	VALLEY PARK, 44, RUE DE LA VALLEE, LUXEMBOURG N4 L-2661
Artal Group S.a.	10 percent owner	VALLEY PARK, 44, RUE DE LA VALLEE, LUXEMBOURG N4 L-2661
Arny Schulman, As Trustee The Armon R. Sharei Irrevocable Gst Trust Of 2016 U/d/t Dated December 29, 2016	10 percent owner	C/O SQZ BIOTECHNOLOGIES COMPANY, 200 ARSENAL YARDS BOULEVARD, SUITE 210, WATERTOWN MA 02472
Marc Elia	director	C/O SQZ BIOTECHNOLOGIES COMPANY, 200 ARSENAL YARDS BOULEVARD, SUITE 210, WATERTOWN MA 02472
Armon Sharei	director, officer: President and CEO	C/O SQZ BIOTECHNOLOGIES COMPANY, 200 ARSENAL YARDS BOULEVARD, SUITE 210, WATERTOWN MA 02472